Evidence Table 72. KQ2—Continuous data—Bleeding time

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Svaneborg 200264 parallel | At low risk for CHD (0-1 risk factors) | ASA | 100 | Omega-3 (EPA, DHA, or both).  | 12 | BP cuff 40 mm Hg- incisions with parallel to the fold of the elbow | Median 9.6Lower: 7.6Upper: 11 | P: <0.05 | NR | p value is for before the injection of ASA | medium |
|  |  Placebo | 6 | Median 7.9Lower: 6.3Upper: 11.5 | P: <0.05 |  |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | Total Cholesterol (mmol/l) | Mean: 3.4 SD: 0.7 | NR | NR | No significant differences between groups. | NA |
| At high risk for CHD | Statins | 20  | placebo | 169 | Mean: 3.4 SD: 0.7 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | LDL-C (mmol/l) | Mean: 1.7SD: 0.5 | NR | NR | No significant differences between groups. | Low |
|  | Placebo | 169 | Mean: 1.8SD: 0.5 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | HDL-C (mmol/L) | Mean: 1.1SD: 0.3 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Mean: 1.1SD: 0.2 | NR | NR |

| Evidence Table 72. KQ2—Continuous data—Bleeding time (continued) |
| --- |
| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | Triglyceride (mmol/l) | Median: 1.1IQR, lower limit: 0.8IQR, upper limit: 1.5 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Median: 1.5IQR, lower limit: 1.1IQR, upper limit: 2.3 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | Systolic blood pressure (mmHg) | Mean: 142SD: 17 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Mean: 143SD: 21 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20  | Omega-3  | 163 | Diastolic blood pressure | Mean: 80SD:11 | NR | NR | No significant differences between groups. | NA |
| Placebo | 169 | Mean: 80SD: 12 | NR | NR |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Ivy method - bleeding time was the time between first and last extravasations and value was mean of three bleeding times | Mean: 6.3SD: 3.1 | Mean: .21 | Mean: 1.01 | ratio of means presented with 90% CI | low-medium |
|  | Placebo | 50 | Mean: 6.2SD: 3.8 | Mean: 2.1 |
| Hansen 199329 crossover | Low and/or Moderate | lovastatin | 40 | Fish/marine oils | 14 | NR | Mean: 390Median SD: 150SE:Lower: Upper: | NR | NR | Reported in graphical form only. | medium |
|  | Placebo | 14 | Mean: 330Median SD: 70SE:Lower: Upper: | NR |
| Kim 201035 crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | determined just before dosing and at 5, 12, and 48 hours after dosing. While applying 40 mm Hg of pressure on the upper arm, we made an incision using a bleeding-time measurement device (Surgicutt, International Technidyne Corp., Edison, New Jersey) on the volar surface of the forearm to measure the bleeding time. | Mean: 6.3Median SD: 2.3SE:Lower: Upper: | Mean:1.1% mean: Median:SD:P: | NR | Range of mean: ginkgo group 3-11.5; To treatment group 2.5-8.5. | medium |
|  | No treatment  | 24 | Mean: 5.3Median SD: 1.7SE:Lower: Upper: | Mean:0.9Median:SD:P:<0.05 |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | measured 0 and 6 h after drug administration by Ivy’s method | Mean: 211Median SD: 70SE: 25Lower: Upper: | NR | NR | 95% CI of mean for individual group data: ginkgo group: 153.00-270.00; No treatment group: 118.00-182.00. | medium |
|  | No treatment  | 10 | Mean: 150Median SD: 42SE: 14Lower: Upper: | NR |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Clopidogrel 75 mg | 105 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | measured 0 and 6 h after drug administration by Ivy’s method | Mean: 148Median SD: 78SE: 28Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 83.00-213.00; No treatment group: 91.00-190.00.  | medium |
|  | No treatment  | 10 | Mean: 141Median SD: 59SE: 21 | NR |
| Mueller 199151 crossover | Low and/or Moderate | aspirin | 325 - single dose | Fish/marine oils | 12 | measured using a Simplate II system. By blinded operator. | Mean: 680Median SD: 302.6SE:Lower: Upper: | Mean:% mean: 18.6Median:SD:P: | NR |  | medium |
|  | Placebo | 12 | Mean: 633.8Median SD: 339.8 | Mean: % mean: 14.5 |